Clinical trial
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT06779773 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- January 22, 2025
- Completion date
- October 31, 2030
- Enrollment
- 489 (actual)
- Sites
- 58
Conditions
As the registry lists them; a condition with its own page is linked.